Eli Lilly Surpasses Expectations, Boosts Revenue Guidance Amid Strong Drug Sales
Eli Lilly’s recent financial performance has significantly exceeded market expectations, driven by robust sales of its diabetes and weight loss drugs. The pharmaceutical giant has subsequently increased its full-year revenue outlook by $3 billion.
Q2 Financial Performance
Eli Lilly reported second-quarter earnings per share (EPS) of $3.92, far surpassing the anticipated $2.60. The company’s revenue reached $11.30 billion, compared to the expected $9.92 billion. This impressive performance is largely attributed to the high demand for its blockbuster drugs, Mounjaro and Zepbound.
Raised Guidance
The company has revised its full-year adjusted earnings guidance to $16.10 to $16.60 per share, up from the previous range of $13.50 to $14. Eli Lilly now anticipates annual revenue between $45.4 billion and $46.6 billion, reflecting a $3 billion increase at both ends of the range. This optimistic outlook is underpinned by the ongoing strong performance of Mounjaro and Zepbound.
Drug Demand and FDA Update
The surge in sales for Mounjaro and Zepbound follows the FDA’s announcement that all doses of these drugs are now available in the U.S., resolving earlier shortages. These incretin drugs, which mimic gut hormones to suppress appetite and regulate blood sugar, have seen demand far outstrip supply. The improved availability is expected to further boost sales.
Stock Performance and Market Cap
Eli Lilly’s stock has climbed more than 30% this year, building on a nearly 60% increase in 2023. This surge reflects strong investor confidence in the company’s weight loss and diabetes treatments, despite high prices, inconsistent insurance coverage, and past supply issues. Eli Lilly’s market capitalization now exceeds $730 billion, making it the largest pharmaceutical company in the U.S.
Dow Jones Price Forecast
Every new Dow Jones analysis as it publishes, today's technical signal and key levels, live price — on one page.
See all Dow Jones forecastsMarket Forecast: Bullish
Given the strong financial results, increased revenue guidance, and resolution of supply issues for key drugs, Eli Lilly’s market outlook remains bullish. The continued demand for Mounjaro and Zepbound, along with investor enthusiasm, is likely to drive further stock appreciation in the near term.
